Latest Breaking News On - Abpro corporation - Page 2 : comparemela.com
Abpro to Become Publicly Traded via Merger with Atlantic Coastal Acquisition Corp II
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Form 8-K Atlantic Coastal Acquisi For: Sep 18
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Abpro to Become Publicly Traded via Merger with Atlantic Coastal Acquisition Corp II (ACAB)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Presented by
With Daniel Lippman
BUSINESS GROUPS CAUGHT FLAT-FOOTED BY CDC MASK GUIDANCE: The Biden administration’s announcement Thursday that fully vaccinated Americans can ditch their masks in most situations is undoubtedly a major milestone in the country’s fight against Covid-19. But trade groups representing the businesses, and a union representing the workers who will now be tasked with enforcing mask-wearing for unvaccinated people, are now scrambling to parse what the guidance means for their members.
Larry Lynch, who as senior vice president of science and industry for the National Restaurant Association handles its Covid operating guidance, said in an interview that the new recommendations may be the industry’s biggest challenge yet. “We don t know how to be the vaccine police,” he said. “CDC didn t do us didn t do the industry, any big favors,” he added, though “it certainly helped consumers.”
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody .
Abpro CorporationDecember 16, 2020 GMT
ABP 300 is a novel human antibody therapy that has been shown to neutralize COVID-19 in preclinical in vivo studies
safety, tolerability, efficacy, and pharmacokinetics
of ABP300 in approximately 2,000 subjects
WOBURN, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) Abpro Corporation today announced the initiation of global Phase 2/3 registrational studies evaluating the safety, tolerability, efficacy, and pharmacokinetics of ABP 300, a human neutralizing antibody for the treatment of COVID-19 derived from patients who have recovered from the SARS-CoV2 infection. The first trial site has been opened with the remainder to follow in 2021. The Phase 1 clinical trial, which included 42 subjects, study results are expected in Q1 2021.